Corrigendum to “Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR” [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103]

Corrigendum Corrigendum to ‘‘Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Ka and mTOR’’ [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103] Phuong T. Le a,⇑, Hengmiao Cheng , Sacha Ninkovic , Michael Plewe , Xiaojun Huang , Hai Wang , Shubha Bagrodia , Shaoxian Sun , Daniel R. Knighton , Caroline M. LaFleur Rogers , Andrew Pannifer , Samantha Greasley , Deepak Dalvie , Eric Zhang c Cancer Chemistry, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States Oncology Research Unit, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States PDM, Pfizer Worldwide Research & Development, La Jolla Laboratories, Pfizer Inc., La Jolla, CA 92121, United States d Pfizer Worldwide Research & Development, Sandwich Laboratories, Pfizer Inc., UK